SHP2 contributes significantly to tumorigenesis in several cancers, including breast cancer, where it participates in cancer cell initiation, invasion, metastasis, and drug resistance, making it an attractive therapeutic target (Song et al., 2021). This evidence concerns the gene PTPN11 and breast carcinoma.